Drugs / AB-SA01
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02757755 | May → Aug 2016 | — | Armata Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT03395769 | — | — | Armata Pharmaceuticals, Inc. | No longer available | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AB-SA01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03395769 ↗ |
| Modality | Other / unclassified | “AB-SA01 consists of three bacteriophages (viruses)” NCT02757755 ↗ |
| Route | Topical | “when topically administered once daily” NCT02757755 ↗ |